title: Oxidative burst inhibitory and cytotoxic amides and lignans from the stem bark of Fagara heitzii (Rutaceae).
abstract: Two amides, heitziamide A and heitziamide B and two phenylethanoids, heitziethanoid A and heitziethanoid B together with thirteen known compounds were isolated from F. heitzii (Letouzey). The structures of all compounds were established by spectroscopic analysis. Nine compounds were evaluated for oxidative burst inhibitory activity in a chemoluminescence assay and for cytotoxicity against PC-3 prostate cancer cells. All compounds exhibited a clear suppressive effect on phagocytosis response upon activation with serum opsonized zymosan at the range of IC(50)=2.0-6.5 microM, but no cytotoxic effect was observed (IC(50)>100 microM).
authors.affiliation: Department of Chemistry, Faculty of Science, University of Douala, P.O. Box 24157, Douala, Cameroon. lmbazze@yahoo.fr
authors.forename: Luc Meva'a
authors.initials: LM
authors.lastname: Mbaze
authors.forename: Jean Alexandre
authors.initials: JA
authors.lastname: Lado
authors.forename: Jean Duplex
authors.initials: JD
authors.lastname: Wansi
authors.forename: Tze Chieh
authors.initials: TC
authors.lastname: Shiao
authors.forename: David Dako
authors.initials: DD
authors.lastname: Chiozem
authors.forename: Muhammad Ahmed
authors.initials: MA
authors.lastname: Mesaik
authors.forename: Muhammad Iqbal
authors.initials: MI
authors.lastname: Choudhary
authors.forename: Marie-Aleth
authors.initials: MA
authors.lastname: Lacaille-Dubois
authors.forename: Jean
authors.initials: J
authors.lastname: Wandji
authors.forename: René
authors.initials: R
authors.lastname: Roy
authors.forename: Norbert
authors.initials: N
authors.lastname: Sewald
mesh_terms: D000577:Amides / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D006574:Heterocyclic Compounds, 2-Ring / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D020128:Inhibitory Concentration 50; D017705:Lignans / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D010587:Phagocytosis / Q000187:drug effects*; D024301:Plant Bark; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D018547:Plant Stems; D011471:Prostatic Neoplasms / Q000188:drug therapy; D016897:Respiratory Burst / Q000187:drug effects*; D027821:Rutaceae / Q000737:chemistry*; D015054:Zymosan / Q000097:blood
chemical_list: D000577:Amides; D000972:Antineoplastic Agents, Phytogenic; D000975:Antioxidants; D006574:Heterocyclic Compounds, 2-Ring; D007155:Immunologic Factors; D017705:Lignans; D010936:Plant Extracts; C545973:heitziamide A; C545974:heitziamide B; C545975:heitziethanoid A; C545976:heitziethanoid B; D015054:Zymosan